Home > Financial Ratios > GLAND PHARMA
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Growth(%) -1.3818.82-27.0420.6731.28

What is the latest Core EBITDA Growth ratio of GLAND PHARMA ?

The latest Core EBITDA Growth ratio of GLAND PHARMA is -1.38 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar2025-1.38
Mar202418.82
Mar2023-27.04
Mar202220.67
Mar202131.28

How is Core EBITDA Growth of GLAND PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2025 -1.38
Negative
Mar2024 18.82
Positive
Mar2023 -27.04
Negative
Mar2022 20.67
-33.92
Mar2021 31.28 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Growth ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹29,949.1 Cr 2.5% 7.1% 23.9% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹437,663.0 Cr 5.2% 3.8% -1.8% Stock Analytics
DIVIS LABORATORIES ₹175,692.0 Cr 2.2% 11.3% 7.9% Stock Analytics
TORRENT PHARMACEUTICALS ₹143,909.0 Cr 0.8% 0.7% 25.7% Stock Analytics
CIPLA ₹107,827.0 Cr 1.3% 9.1% -15.7% Stock Analytics
DR REDDYS LABORATORIES ₹107,500.0 Cr -3.5% 2.7% 10.3% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

2.5%

7.1%

23.9%

SENSEX

0.8%

5%

-2.5%


You may also like the below Video Courses